M&A Deal Summary

Biogen Acquires Reata

On July 28, 2023, Biogen acquired life science company Reata for 7.3B USD

Acquisition Highlights
  • This is Biogen’s 8th transaction in the Life Science sector.
  • This is Biogen’s largest (disclosed) transaction.
  • This is Biogen’s 5th transaction in the United States.
  • This is Biogen’s 1st transaction in Texas.

M&A Deal Summary
Date 2023-07-28
Target Reata
Sector Life Science
Buyer(s) Biogen
Deal Type Add-on Acquisition
Deal Value 7.3B USD
Advisor(s) Goldman Sachs (Financial)
Vinson & Elkins (Legal)

Target

Reata

Plano, Texas, United States
Reata engages in developing novel oral anti-inflammatory drugs targeting NrF2. This important biological target has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata was founded in 2002 and is based in Plano, Texas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biogen

Cambridge, Massachusetts, United States
Category Company
Founded 1978
Sector Life Science
Employees7,570
Revenue 9.8B USD (2023)
DESCRIPTION
Entrance to Biogen office in Weston, Massachusetts.
Entrance to Biogen office in Weston, Massachusetts.

Biogen is a biopharmaceutical company focused on discovering, developing, and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen was founded in 1978 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 8 of 9
Sector (Life Science) 8 of 9
Type (Add-on Acquisition) 6 of 7
State (Texas) 1 of 1
Country (United States) 5 of 6
Year (2023) 1 of 1
Size (of disclosed) 1 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-13 Pfizer - CK 1 Business

New York, New York, United States

Pfizer, Inc. - CK 1 Business is a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.

Buy $75M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-22 HI-Bio

South San Francisco, California, United States

HI-Bio is a clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). The company’s felzartamab is a CD38-targeted antibody shown in clinical studies to deplete CD38+ cells, including plasma and natural killer (NK) cells, which are implicated in a range of indications including antibody-mediated rejection (AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary membranous nephropathy (PMN). HI-Bio is based in South San Francisco, California.

Buy -
Mergr

Product

Company

Legal